Most non–small cell lung cancer (NSCLC) tumors develop resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) within 10 to 16 months after the initiation of EGFR-TKI therapy [1–6]. Here, EGFR is linked to lung cancer.